PrEvention of Posttraumatic Joint contractuRes With Ketotifen 2

PHASE3CompletedINTERVENTIONAL
Enrollment

395

Participants

Timeline

Start Date

April 26, 2019

Primary Completion Date

September 29, 2024

Study Completion Date

December 17, 2024

Conditions
Elbow FractureElbow InjuryElbow Dislocation
Interventions
DRUG

Lactose Placebo

One capsule by mouth twice per day

DRUG

Ketotifen Fumarate 2mg

2 mg tablets (over-encapsulated into one capsule) by mouth twice per day

DRUG

Ketotifen Fumarate 5mg

5 mg tablets (over-encapsulated into one capsule) by mouth twice per day

Trial Locations (15)

21201

University of Maryland Medical Centre, Baltimore

28204

Carolinas Medical Center, Charlotte

05401

University of Vermont Medical Center, Burlington

T1Y 6J4

Peter Lougheed Centre, Calgary

T2N 2T9

Foothills Medical Centre, Calgary

T3M 1M4

South Health Campus, Calgary

T8N 6C4

Sturgeon Community Hospital, St. Albert

V3L 3W7

Royal Columbia Hospital, New Westminster

V6Z 1Y6

St. Paul's Hospital, Vancouver

B3H 2Y9

Queen Elizabeth II Health Sciences Centre, Halifax

N6A 4V2

St. Joseph's Health Care London, London

K1H 8L6

The Ottawa General Hospital, Ottawa

K1Y 4E9

The Ottawa Civic Hospital, Ottawa

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

M5B 1W8

St. Michael's Hospital, Toronto

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

University of Calgary

OTHER

NCT03582176 - PrEvention of Posttraumatic Joint contractuRes With Ketotifen 2 | Biotech Hunter | Biotech Hunter